Avutometinib Potassium Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 0.8 mg, 200 mg
Reference Brands: Avmapki (USA), Fakzynja (USA)
Category:
Oncology Cancer Care
Avutometinib potassium is available in Capsules
and strengths such as 0.8 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Avutometinib potassium is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Avutometinib potassium can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Avutometinib potassium (CH5126766) is a small-molecule kinase inhibitor designed to block the RAF/MEK signaling pathway in cancer cells. It functions as a RAF/MEK clamp, potently inhibiting RAF and MEK kinase activity while inducing dominant-negative RAF-MEK complexes that prevent MEK phosphorylation by ARAF, BRAF, and CRAF. This mechanism effectively suppresses tumor cell proliferation, particularly in cell lines harboring KRAS mutations, including pancreatic ductal adenocarcinoma (PDAC) models. Preclinical studies demonstrate that Avutometinib potassium inhibits tumor growth and improves survival in KRAS/p53 pancreatic cancer mouse models. The compound shows promise for targeted therapy research in low-grade serous ovarian carcinoma (LGSOC), ovarian cancer, and pancreatic cancers, offering a precision oncology approach to treatment. Administered orally in capsule form, Avutometinib potassium is being investigated both as a single agent and in combination therapies to enhance anti-cancer efficacy. Its ability to disrupt critical cancer cell signaling pathways highlights its potential as a valuable therapeutic option in the development of next-generation treatments for KRAS-driven malignancies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing